All
FDA Accepts Application for Zolbetuximab in Gastric, GEJ Cancers
July 10th 2023If the FDA approves zolbetuximab, this would mark the first CLDN18.2-targeting monoclonal antibody to treat patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Venclexta Plus Gazyva Induces Minimal Residual Disease, Improves Survival in CLL
July 9th 2023Fit patients with chronic lymphocytic leukemia treated with Venclexta and Gazyva, regardless of the use of Imbruvica, experienced improvements in progression-free survival and were more likely to obtain undetectable minimal residual disease.